Identification of Candidate Inhibitors to SARS-CoV-2’s Enzymes and Potential Disruptors of Its Structural Proteins’ Interactions
Ali Mohammadian, Mahdieh Jadaliha, Aylar Imanpour, Hamed Pourvali Moghadam, AmirHossein Jahangir · 2025
Read Identification of Candidate Inhibitors to SARS-CoV-2’s Enzymes and Potential Disruptors of Its Structural Proteins’ Interactions by Ali Mohammadian, Mahdieh Jadaliha, Aylar Imanpour, Hamed Pourvali Moghadam, AmirHossein Jahangir (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12885199.txt.
Description
Ali Mohammadian and co-authors screen in 2025 thousands of approved drugs for ones that might jam the COVID-19 virus. Experience with HIV teaches that hitting a virus at several points curbs resistance, so the hunt covered both the virus's enzymes and its structural proteins. In all, 2,371 approved drugs were tested in software.
Three docking programs ran the screen, and top hits from the first were rechecked with the other two. The standout suggestion: direct-acting antivirals built for hepatitis C may also work against this virus. The authors present repurposing as a fast route to candidate treatments for new diseases.
Catalog record
| CREATOR | Ali Mohammadian, Mahdieh Jadaliha, Aylar Imanpour, Hamed Pourvali Moghadam, AmirHossein Jahangir |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |